Research Analysis · Men’s healthy aging
TRAVERSE found cardiovascular noninferiority—not a longevity benefit
In selected men with symptoms, repeated low testosterone and elevated cardiovascular risk, the primary MACE outcome was 7.0% with testosterone and 7.3% with placebo. That met a noninferiority boundary; it did not prove cardiovascular benefit, overall safety or longer life.
Discovery, counterevidence, claim mapping, identifiers, funding, correction state and prose were reviewed before release.
Evidence at a glance
One large cardiovascular noninferiority trial
- Study type
- Randomized, double-blind cardiovascular noninferiority trial
- Studied in
- Humans
- Participants / sample
- 5,246 men age 45–80 with symptoms, two fasting testosterone values below 300 ng/dL, and preexisting or high cardiovascular risk
- Publication status
- Peer reviewed; no linked correction, retraction or expression of concern identified as of verification
- Outcome type
- Cardiovascular death, nonfatal myocardial infarction or nonfatal stroke; other safety events reported separately
- Evidence maturity
- Large human randomized evidence for one composite over about 33 months mean follow-up
- Conflicts / funding
- FDA-required postmarketing trial funded by an industry consortium led by AbbVie
- Our assessment
- Met the prespecified MACE noninferiority criterion; did not establish cardiovascular benefit, universal safety or longevity benefit
Read this first
Three takeaways
- Primary MACE occurred in 182 of 2,601 men (7.0%) assigned testosterone and 190 of 2,603 (7.3%) assigned placebo; hazard ratio 0.96, 95% CI 0.78–1.17.
- The upper confidence boundary stayed below the prespecified 1.5 noninferiority margin. Noninferiority means the trial ruled out the specified amount of excess risk for this composite—not that testosterone improved cardiovascular outcomes.
- Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often with testosterone. The trial’s duration and population do not settle every safety or longevity question.
Keep outcomes separate
Noninferiority, benefit, safety and longevity are not synonyms
Noninferiority
The primary composite stayed within a prespecified margin; this was not a superiority result.
Other events
Atrial fibrillation, acute kidney injury and pulmonary embolism were reported more often with testosterone.
Formulation
TRAVERSE tested monitored daily 1.62% transdermal gel, not every route, dose or use pattern.
Longevity
The trial did not test biological-age reversal, healthspan extension or lifespan extension.
The bottom line
TRAVERSE provides substantial reassurance about one prespecified cardiovascular composite in its enrolled population. It does not make testosterone a cardiovascular-prevention treatment, erase other safety signals or demonstrate an anti-aging benefit.
What researchers did
Investigators randomized 5,246 men age 45 to 80 who had symptoms, two fasting testosterone concentrations below 300 ng/dL, and preexisting cardiovascular disease or elevated risk. Participants used daily 1.62% testosterone gel adjusted to a protocol range or placebo gel.
What they found
The primary composite occurred in 7.0% assigned testosterone and 7.3% assigned placebo; hazard ratio 0.96, 95% CI 0.78–1.17. The upper boundary was below the prespecified 1.5 noninferiority margin. Mean treatment duration was about 21.7 months and mean follow-up about 33 months.
How strong is the evidence?
This is a large randomized outcome trial with adjudicated cardiovascular events. Its strongest conclusion is narrow: testosterone was noninferior to placebo for the named composite under the named margin in selected men using monitored gel.
What this does not show
The result does not prove cardiovascular benefit, overall safety, safety beyond the observed follow-up, or applicability to men without symptoms and repeated low measurements. It does not apply automatically to injections, pellets, oral products, compounded products, bodybuilding use or supraphysiologic dosing.
Safety, regulation and conflicts
Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often with testosterone. FDA’s February 2025 action removed cardiovascular-risk boxed-warning language while adding class-wide blood-pressure warnings; a June 18, 2026 request separately revised age-related-use and prostate language. TRAVERSE was industry funded.
What happens next
Longer follow-up, formulation-specific data and clearer estimates for individual safety outcomes could narrow uncertainty. FDA pages and individual product labels can change and should be checked as dated regulatory context, not read as proof of longevity benefit.
Educational boundary
This article explains a population trial and dated regulator records. It is not personalized medical advice and does not diagnose low testosterone, establish eligibility, interpret laboratory results or tell a person to start, stop or change treatment.
Primary sources
Sources, roles and limits
- TRAVERSE cardiovascular trial
- Identifier
- PMID:37326322 · DOI:10.1056/NEJMoa2215025 · NCT03518034
- Role
- Primary randomized cardiovascular support
- Limitation
- Selected symptomatic high-risk men using monitored transdermal gel; mean follow-up about 33 months.
- TRAVERSE registry record
- Identifier
- NCT03518034
- Role
- Trial identity, design, sponsor and posted-results context
- Limitation
- Registration and posted results are not government validation of benefit or overall safety.
- FDA class-wide labeling changes
- Identifier
- FDA · February 28, 2025
- Role
- Dated cardiovascular and blood-pressure label context
- Limitation
- The 2025 notice preceded the separate June 2026 limitation-of-use request.
- HHS announcement of requested testosterone-label updates
- Identifier
- HHS/FDA · June 18, 2026
- Role
- Dated limitation-of-use and prostate-label context
- Limitation
- A requested label revision is not a treatment recommendation or longevity result.
- Current FDA Testosterone Information
- Identifier
- FDA page checked August 3, 2026
- Role
- Current regulator wording and TRAVERSE summary
- Limitation
- Product labels and regulator pages can change; current indication language remains formulation and condition specific.
Connected topics
Continue through the knowledge system
Continue with real coverage
Keep reading
These are learning paths, not rankings or recommendations.
Another cardiovascular trial where absolute outcomes and treatment context matter
SPRINT reduced cardiovascular events—not aging itself
Intensive treatment lowered cardiovascular events and mortality in eligible high-risk adults, with more hypotension, electrolyte problems and kidney injury.
Evidence scopeHuman clinical outcomes · large randomized trial
Another treatment question with age-specific cardiovascular evidence
Statin evidence changes with age, risk and prevention setting
Evidence is clearer after vascular disease than for starting primary prevention after age 75, and it does not establish longer life.
Evidence scopeHuman clinical outcomes · trials and pooled evidence
Another hormone trial separating indicated treatment from longevity claims
Menopausal hormone therapy treats symptoms. WHI did not show a longevity benefit
WHI found a formulation-specific mix of benefits and harms, no overall 18-year mortality difference, and no basis for general longevity prevention.
Evidence scopeHuman disease outcomes and mortality · randomized trials
Disclosures and history
- August 3, 2026 — source discovery and independent verification completed before prose drafting.
- August 3, 2026 — atomic population, formulation, outcome, safety, funding and longevity boundaries reviewed.
- Corrections: no linked correction, retraction or expression of concern identified for the featured primary papers as of verification; regulator and registry records must be rechecked when this story is updated.